Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

BNTXBioNTech SESigning up patients

Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors

Advanced Solid Tumor Cancer

0Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

No warning signs right now. That's why the score is 0.

Score over time

Stage
Phase 1/2
Patients
533 (planned)
Started
Mar 30, 2026
Main results expected
Oct 2030
Fully finished
Oct 2030
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • All parts - Number and percentage of participants with treatment emergent adverse events (TEAEs)

    Measured over: From the time of initiation of the first dose of BNT3214 until 90 days after the last dose of BNT3214

  • All parts - Number and percentage of participants with dose interruptions, reductions, and discontinuation of BNT3214 due to TEAEs

    Measured over: Up to 24 months

  • Parts A and B only - Number and percentage of participants with dose limiting toxicities (DLTs)

    Measured over: From first dose up to 28 days

  • Part C only - Objective response rate (ORR)

    Measured over: Up to 30 months

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • none

Raw record changes

  • none yet

Trial ID NCT07455734 · record last updated 2026-08-13 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT07455734) ↗